GenMark Diagnostics, Inc. GNMK
Set alert
— — —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 1.77B
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- 133.56
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 3, 2021
- 50-d avg
- 23.99
- 200-d avg
- 16.94
- 1y target
- 22.52
Analyst view
Consensus: hold
Hold
Price target (mean) 22.52
- Target (low)
- 21.00
- Target (mean)
- 22.52
- Target (high)
- 24.05
Ratings (0m) 8 7 buy · 1 hold · 0 sell
- Strong buy4
- Buy3
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 8
- 1 month ago 6
- 2 months ago 7
- 3 months ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.00 | 0.00 – 0.00 | -0.12 | 0.0% | 49.00M | +26.5% | 0 |
| Next quarter | 0.00 | 0.00 – 0.00 | -0.07 | 0.0% | 41.10M | +2.5% | 0 |
| Current year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 192.00M | +11.9% | 0 |
| Next year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 211.60M | +10.2% | 0 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 17, 2021 | BTIG | Downgrade | Buy | Neutral |
| Mar 17, 2021 | Cowen & Co. | Downgrade | Outperform | Market Perform |
| Mar 16, 2021 | Canaccord Genuity | Downgrade | Buy | Hold |
| Mar 15, 2021 | Needham | Downgrade | Buy | Hold |
| Feb 16, 2021 | Canaccord Genuity | Maintained | — | Buy |
| Aug 5, 2020 | Needham | Maintained | — | Buy |
| Jul 8, 2020 | Canaccord Genuity | Maintained | — | Buy |
| Jul 8, 2020 | BTIG | Reiterated | — | Buy |
| Jul 8, 2020 | Needham | Maintained | — | Buy |
| May 5, 2020 | Needham | Maintained | — | Buy |
| Mar 3, 2020 | Needham | Maintained | — | Buy |
| Feb 11, 2020 | Raymond James | Downgrade | Outperform | Market Perform |
| Dec 11, 2019 | JP Morgan | Downgrade | Overweight | Neutral |
| Nov 7, 2019 | Raymond James | Maintained | — | Outperform |
| Oct 30, 2018 | Canaccord Genuity | Maintained | Buy | Buy |
| Jul 31, 2018 | Canaccord Genuity | Maintained | Buy | Buy |
| Jun 29, 2018 | Canaccord Genuity | Maintained | Buy | Buy |
| Feb 28, 2018 | Canaccord Genuity | Maintained | Buy | Buy |
| Nov 5, 2017 | Raymond James | Downgrade | Outperform | Market Perform |
| Nov 3, 2017 | Canaccord Genuity | Maintained | — | Buy |
| Sep 19, 2017 | Bank of America | Initiated | — | Buy |
| Sep 16, 2016 | Cowen & Co. | Upgrade | Market Perform | Outperform |
| Jul 29, 2016 | JP Morgan | Maintained | — | Overweight |
| Feb 24, 2016 | JP Morgan | Maintained | — | Overweight |
| May 6, 2015 | Canaccord Genuity | Maintained | — | Buy |
| Aug 12, 2014 | Raymond James | Maintained | — | Outperform |
| May 6, 2014 | Raymond James | Maintained | — | Outperform |
| May 6, 2014 | JP Morgan | Maintained | — | Overweight |
| Dec 19, 2013 | Needham | Initiated | — | Buy |
| Oct 2, 2013 | Raymond James | Maintained | — | Outperform |